TY - JOUR AU - Dupuis, Maria Luisa AU - Ascione, Alessandro AU - Palmisano, Lucia AU - Vella, Stefano AU - Cianfriglia, Maurizio PY - 2013 DA - 2013/09/20 TI - Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells JO - BMC Pharmacology and Toxicology SP - 47 VL - 14 IS - 1 AB - Raltegravir (Isentress®)(RALT) has demonstrated excellent efficacy in both treatment-experienced and naïve patients with HIV-1 infection, and is the first strand transfer integrase inhibitor to be approved for use in HIV infected adults worldwide. Since the in vivo efficacy of this class of antiviral drugs depends on their access to intracellular sites where HIV-1 replicates, we analyzed the biological effects induced by RALT on human MDR cell systems expressing multidrug transporter MDR1-P-glycoprotein (MDR1-Pgp). SN - 2050-6511 UR - https://doi.org/10.1186/2050-6511-14-47 DO - 10.1186/2050-6511-14-47 ID - Dupuis2013 ER -